OTCMKTS:RLMD

Relmada Therapeutics Stock News

Healthcare > Biotechnology

Buy RLMD

*Your capital is at risk

$6.33

-0.0900 (-1.40%)

At Close: Jun 03, 2026

Relmada Therapeutics To Present NDV-01 Data at AUA2025

07:30am, Monday, 14'th Apr 2025

CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presenta

Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript

08:07pm, Thursday, 27'th Mar 2025

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors, IR Sergio Traversa - CEO Maged Shenouda - CF

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

04:05pm, Thursday, 27'th Mar 2025

Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

09:00am, Wednesday, 26'th Mar 2025

CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing inn

Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.

07:30am, Tuesday, 25'th Mar 2025

NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 pa

Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB

07:30am, Thursday, 06'th Feb 2025

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB

Relmada discontinues late-stage trials for depression drug, explores sale

08:11am, Monday, 09'th Dec 2024

Relmada Therapeutics said on Monday it would discontinue the two late-stage studies planned for the development of its depression drug and explore strategic alternatives including a sale.

Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

07:30am, Monday, 09'th Dec 2024

Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize Shareholder Value Relmada Therapeutics has Commenced a Process to Explore Strategic Alternatives to Maximize

Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why

02:02pm, Wednesday, 04'th Dec 2024

On Wednesday, Relmada Therapeutics, Inc. RLMD announced a preplanned interim analysis of the Reliance II Phase 3 study.

Relmada's depression drug unlikely to meet main trial goal, analysis shows

08:00am, Wednesday, 04'th Dec 2024

Relmada Therapeutics' depression treatment is "unlikely" to meet the main goal of a late-stage trial, it said on Wednesday, citing an independent data monitoring committee's analysis.

Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance

07:30am, Wednesday, 04'th Dec 2024

The DMC did not identify any new safety concerns Relmada to evaluate potential next steps for the REL-1017 program Relmada to continue to focus on the development of REL-P11 for metabolic disease Relm

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by